Free Trial
NASDAQ:BLRX

BioLineRx (BLRX) Stock Price, News & Analysis

BioLineRx logo
$4.47 +0.15 (+3.47%)
As of 10:02 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About BioLineRx Stock (NASDAQ:BLRX)

Key Stats

Today's Range
$4.28
$4.39
50-Day Range
$3.09
$5.93
52-Week Range
$2.30
$35.60
Volume
8,029 shs
Average Volume
233,417 shs
Market Capitalization
$19.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.00
Consensus Rating
Strong Buy

Company Overview

BioLineRx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

BLRX MarketRank™: 

BioLineRx scored higher than 54% of companies evaluated by MarketBeat, and ranked 470th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioLineRx has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    BioLineRx has only been the subject of 2 research reports in the past 90 days.

  • Read more about BioLineRx's stock forecast and price target.
  • Earnings Growth

    Earnings for BioLineRx are expected to grow in the coming year, from ($5.80) to ($5.60) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioLineRx is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioLineRx is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BioLineRx has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about BioLineRx's valuation and earnings.
  • Percentage of Shares Shorted

    4.65% of the float of BioLineRx has been sold short.
  • Short Interest Ratio / Days to Cover

    BioLineRx has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioLineRx has recently increased by 19.29%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    BioLineRx does not currently pay a dividend.

  • Dividend Growth

    BioLineRx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.65% of the float of BioLineRx has been sold short.
  • Short Interest Ratio / Days to Cover

    BioLineRx has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioLineRx has recently increased by 19.29%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    BioLineRx has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for BioLineRx this week, compared to 1 article on an average week.
  • Search Interest

    7 people have searched for BLRX on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.
  • MarketBeat Follows

    12 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioLineRx insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.10% of the stock of BioLineRx is held by insiders.

  • Percentage Held by Institutions

    Only 1.56% of the stock of BioLineRx is held by institutions.

  • Read more about BioLineRx's insider trading history.
Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

BLRX Stock News Headlines

Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.
15 Best Growth Stocks to Invest in for the Next 5 Years
BioLineRx upgraded to Buy from Hold at JonesResearch
See More Headlines

BLRX Stock Analysis - Frequently Asked Questions

BioLineRx's stock was trading at $8.56 on January 1st, 2025. Since then, BLRX shares have decreased by 49.5% and is now trading at $4.32.

BioLineRx Ltd. (NASDAQ:BLRX) posted its earnings results on Tuesday, May, 27th. The biotechnology company reported $1.39 earnings per share for the quarter, beating analysts' consensus estimates of ($0.84) by $2.23. The biotechnology company had revenue of $11.75 million for the quarter, compared to the consensus estimate of $7.72 million. BioLineRx had a negative net margin of 15.21% and a negative trailing twelve-month return on equity of 23.93%.
Read the conference call transcript
.

Shares of BioLineRx reverse split before market open on Thursday, January 30th 2025.The 1-40 reverse split was announced on Friday, January 17th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioLineRx investors own include Savara (SVRA), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), Brainstorm Cell Therapeutics (BCLI) and Tesla (TSLA).

Company Calendar

Last Earnings
5/27/2025
Today
7/09/2025
Next Earnings (Estimated)
8/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BLRX
CIK
1498403
Employees
40
Year Founded
N/A

Price Target and Rating

High Price Target
$26.00
Low Price Target
$26.00
Potential Upside/Downside
+501.9%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$9.22 million
Pretax Margin
-15.21%

Debt

Sales & Book Value

Annual Sales
$28.94 million
Price / Cash Flow
N/A
Book Value
$4.04 per share
Price / Book
1.07

Miscellaneous

Free Float
4,216,000
Market Cap
$18.40 million
Optionable
Optionable
Beta
1.25
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:BLRX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners